Journal
ORGANIC PROCESS RESEARCH & DEVELOPMENT
Volume 18, Issue 3, Pages 417-422Publisher
AMER CHEMICAL SOC
DOI: 10.1021/op4003196
Keywords
-
Categories
Funding
- Institute for OneWorld Health (PATH)
- Bill & Melinda Gates Foundation
Ask authors/readers for more resources
A new commercial-scale alternative manufacturing process to produce a complementary source of artemisinin to supplement the plant-derived supply is described by conversion of biosynthetic artemisinic acid into semisynthetic artemisinin using diastereoselective hydrogenation and photooxidation as pivotal steps. This process was accepted by Prequalification of Medicines Programme (PQP) in 2013 as a first source of nonplant-derived-artemisinin in industrial scale from Sanofi production facility in Garessio, Italy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
